Mauna Kea Technologies: Details of the Capital Increase

Endomicroscopy specialist Mauna Kea Technologies is launching a capital increase of €5 million to €8 million. Scheduled for November, it is part of a recently approved safeguard plan. Private financing via shares with warrants (ABSA) is underway, with one investor committing €2.7 million.

Current and future investors will receive share subscription warrants (BSA). A capital stabilization adjustment is also planned. The expected financing should enable the company to achieve profitability and self-financing by 2027.

The debt reduction from €40 million to €12 million has been approved. The plan will be finalized in November, subject to approval by the Paris Economic Court.